Search

Copyright of Acta Stomatologica Naissi is the property of Clinic of Stomatology Nis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: As the most common primary malignant intracranial tumor, glioblastoma has a poor prognosis with limited treatment options. It has a high propensity for recurrence, invasion, and poor immune prognosis due to the complex tumor microenvironment. Methods: Six groups of samples from four datasets were included in this study. We used consensus ClusterPlus to establish two subgroups by the EMT-related gene. The difference in clinicopathological features, genomic characteristics, immune infiltration, treatment response and prognoses were evaluated by multiple algorithms. By using LASSO regression, multi-factor Cox analysis, stepAIC method, a prognostic risk model was constructed based on the final screened genes. Results: The consensusClusterPlus analyses revealed two subtypes of glioblastoma (C1 and C2), which were characterized by different EMT-related gene expression patterns. C2 subtype with the worse prognosis had the more malignant clinical and pathology manifestations, higher Immune infiltration and tumor-associated molecular pathways scores, and poorer response to treatment. Additionally, our EMT-related genes risk prediction model can provide valuable support for clinical evaluations of glioma. Conclusions: The assessment system and prediction model displayed good performance in independent prognostic risk assessment and individual patient treatment response prediction. This can help with clinical treatment decisions and the development of effective treatments. [ABSTRACT FROM AUTHOR]

Background. Rapid development of radiotherapeutic techniques and implementation of radiation therapy (RT) nanotechnologies in practice, taking into account principles of radiobiology, ensures that the planned dose will be delivered to the target volume with minimal irradiation of healthy tissues while maintaining the guaranteed RT quality. Therefore, further advance of RT involves not only implementation of the new technologies in radiation practice, but also the intensive developments in fields of radiation medicine and clinical radiobiology. Objective: search for optimal models of the high-energy (HDR - high dose rate) brachytherapy (BT) using the 192Ir source in comparison with effects of the reference gamma radiation from 60Co, thereby, to increase the effectiveness of chemoradiation therapy (CRT) of gynecological cancer patients (GCPs) with minimal radiation loads on critical organs and tissues in the tumor environment. The radiobiological study was aimed to determine the feasibility of using the transmembrane potential (TMP) and intensity of reactive oxygen species (ROS) production in peripheral blood lymphocytes (PBL) as predictors of radiosensitivity of non-malignant cells from the tumor environment or its bed in order to minimize the RT complications in GCPs. Materials and methods. Patients (n = 115) with cancer stages II-III, T2-3N0-1M0 were managed with comprehensive conservative treatment. Three groups of patients were selected depending on the applied HDR BT method against a background of the administered chemosensitizing agents. Blood samples of GCPs (n = 24) before the RT initiation and of apparently healthy individuals (AHIs, i.e. the control group, n = 18) were taken for the radiobiological research. Results. Review of the direct results of 60Co or 192Ir sources use in HDR BT and of the follow-up data showed the increased tumor positive response in the main study groups after CRT course by respectively 16.6 % and 20.1 % in comparison with 60Со HDR BT administration. Concerning local reactions it was noted that grade II radiation reactions were almost absent in the main groups. According to the results of radiobiological studies, it was established that TMP level in PBL of GCPs was 1.36 times higher than in AHIs. Conclusions. Thus, the emerging of late radiation injuries depended on the accuracy of of individual computer planning and correct reproduction of the planned RT course, timely correction of treatment programs, use of a complex of rational medical prophylaxis, severity of tumor process and concomitant disorders, as well as on the used type of HDR radiation sources (192Ir and 60Co). Changes in TMP values and intensity of ROS production in PBL of GCPs in comparison with AHIs, and the high values of these parameters in PBL of individual patients are a rationale to specify them as additional indicators characterizing the possibility of radiation complications before the RT planning. [ABSTRACT FROM AUTHOR]

Objective: identification of the relevant biochemical indices of blood radiosensitivity in endometrial cancer patients under the test irradiation in a wide range of doses. Materials and methods. Peripheral blood samples were drawn for assay in the newly diagnosed endometrial cancer patients (study group, n = 42) and healthy donors (control group, n = 27). A set of biochemical values was reviewed to identify and justify the prognostic markers of cell radiosensitivity in the tumor environment featuring gradual development of oxidative stress, namely the intensity of superoxide anion-radical (О2•-) generation, pro-/antioxidant ratio (PAR), and malondialdehyde (MDA) content. Predictive values were selected through the construction and analysis of «dose-response» dependencies of the studied parameters during X-ray test exposure in a dose range of 0.5-3.0 Gy. Nature of the dose curves was determined using linear and linear-quadratic regression models. Results. The 3.2 times higher MDA content was found in blood plasma of endometrial cancer patients compared to the control group, namely (60.87 ± 4.93) μM/g of protein versus (18.93 ± 2.05) μM/g of protein (р < 0.05). The raise in MDA content along with increase in the test radiation dose (in a range of 0.5-3.0 Gy) was approximated by the linear regression model Y = 67.44 + 12.52D, R2 = 0.85. A 1.29-1.74-fold increase in the mean group value depending on the radiation dose was recorded (р < 0.05). Effects of low-dose irradiation (0.5 Gy) were differentiated as (85.03 ± 8.9) against the initial MDA level of (60.87 ± 4.93) μM/g of protein. There was an increase in the intensity of О2•- generation in blood lymphocytes and elevated PAR value in hemolysate from endometrial cancer patients compared to healthy donors by 1.34 and 1.30 times (р < 0.05) respectively, which indicated the intensification of pro-oxidant processes in patients. The inter-individual peculiarities of the blood reaction-response to radiation were revealed according to parameters depending on the initial values, which characterize them only as additional prognostic biomarkers in radiation treatment planning for gynecological cancer patients. Conclusions. It has been proven that the linear nature of dose dependence of MDA content in blood plasma of endometrial cancer patients and response to low-dose irradiation of are the basic criteria for recognizing MDA as a relevant prognostic biochemical indicator of radiosensitivity of healthy cells from the tumor environment. The content of MDA in blood plasma of gynecological cancer patients should be taken into account in order to identify the subjects with a high risk of radiation complications. [ABSTRACT FROM AUTHOR]

Copyright of Jornal Brasileiro de Patologia e Medicina Laboratorial is the property of Sociedade Brasileira de Patologia Clinica and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)